Biotech Wealth Starts Here - 6/7

The FDA Is Moving — And Most Biotech Investors Are Looking the Wrong Way           

A quick note from Behind the Markets

Good morning.

Biotech investors get seduced by narratives.

Wall Street loves narratives because they sell deal flow.

But biotech wealth is built on something boring:

Regulatory outcomes.

1) The FDA is quietly approving more new drugs than most investors realize

The FDA's running list of 2026 novel drug approvals shows 20 approvals so far, with three new approvals dated 5/29 alone — spanning everything from anesthesia to antibiotics to COVID post-exposure prophylaxis.

This matters because it punches a hole in the lazy "FDA is a bottleneck" story.

Yes, regulation is hard.

But the agency is also moving product through. And when the FDA moves, capital rotates.

Not into the loudest company.

Into the company that just got de-risked.

One name that tells this story clearly:

Company: Corcept Therapeutics (SYM: CORT)
Mid-cap biopharma; cortisol modulation platform across oncology, endocrinology, and neurology

Corcept's ovarian cancer drug Lifyorli (relacorilant) was approved on March 25 — more than two months ahead of its scheduled FDA review date. The stock surged roughly 40% on the news. Within weeks, Lifyorli was added to NCCN Guidelines as a preferred regimen for platinum-resistant ovarian cancer — one of the fastest guideline inclusions in recent memory.

Here's the business case: Corcept raised its full-year 2026 revenue guidance to $950 million–$1.05 billion. The company has $515 million in cash, a deep pipeline in Cushing's syndrome, oncology, MASH, and ALS — and analysts have recently raised price targets as high as $135.

Corcept is currently trading around $72. The average analyst target sits near $89. That's a meaningful gap — and it exists because the market is still digesting how fast this company went from "single-product story" to "multi-franchise platform."

That's what FDA de-risking looks like in real life.

Bottom line: The market is obsessed with FDA risk… but it often underprices what happens after that risk gets removed.

2) A retail investor framework: trade the second-order effects, not the press release

Most people buy biotech on the announcement.

That's usually the worst time.

The smarter play is to map what an approval forces next: manufacturing scale-up, payer negotiations and pricing, competition response, partnering or acquisition interest.

An approval is not the end of the story.

It's the start of the business model.

That's where Wall Street is often late. Especially in underfollowed small- and mid-caps.

And if you're looking for a company that profits from that exact transition — from clinical milestone to commercial reality — there's one that essentially built the toll road.

Company: Halozyme Therapeutics (SYM: HALO)
Drug delivery platform company; licenses ENHANZE technology to major pharma partners.

Halozyme doesn't develop its own drugs. It licenses a proprietary technology — ENHANZE — that allows pharma companies to convert slow IV infusions into fast subcutaneous injections. Think of it as the plumbing underneath the drug launch.

Every time a partner commercializes an ENHANZE-enabled product, Halozyme collects royalties. And those partners include some of the biggest names in the business — argenx, Takeda, Johnson & Johnson, Roche.

The numbers tell the story. In Q1 2026, Halozyme reported 42% year-over-year revenue growth and 43% royalty revenue growth. Royalty revenue alone is expected to exceed $1 billion for the full year. The company just signed three new licensing deals — with Vertex, Oruka, and GSK — and announced a $1 billion share buyback program.

Halozyme is currently trading around $68. The average analyst price target is roughly $87. That's a company generating over a billion in royalties, buying back its own stock hand over fist, and trading at a discount to where the Street says it should be.

You don't need to pick the winning drug. You just need to own the infrastructure that every winning drug needs to reach patients.

Bottom line: Approvals create operational winners and losers. The edge is identifying who can actually commercialize — and who just got a temporary pop.

3) The contrarian truth: "FDA momentum" changes M&A behavior

Here's something retail investors rarely hear:

Big pharma buys when it can see a path.

The more clarity the FDA provides, the more executable deals become. A steady cadence of approvals and clear labels reduces uncertainty.

And uncertainty is what kills acquisitions.

The math here is stark. By some estimates, $236 billion in annual pharmaceutical revenue is at risk from patent expirations on blockbusters like Humira, Keytruda, and Opdivo. That's not a rounding error. That's a hole the size of a Fortune 50 company's entire top line — and Big Pharma has to fill it.

So if the FDA stays active, you should expect more licensing, more bolt-on deals, and more "platform" acquisitions for commercial infrastructure.

This isn't speculation. In 2026 alone, at least 33 biopharma M&A transactions have already been tracked — including Gilead's ~$7.8 billion deal for Arcellx, Lilly's acquisitions of Centessa and Orna Therapeutics, and Pfizer's $10 billion acquisition of Metsera. The tape is selective but active: buyers are paying premiums for approved products, late-stage assets, and platform technology.

If you want broad exposure to that M&A tailwind — especially among the smaller biotechs most likely to get acquired — there's a clean way to play it.

ETF: SPDR S&P Biotech ETF (SYM: XBI)
Equal-weighted biotech ETF covering small- and mid-cap names across the U.S. biotech sector

XBI doesn't concentrate in mega-cap pharma the way the iShares IBB does. It equal-weights its holdings, which means smaller, earlier-stage companies carry just as much influence as the big names. That's exactly what you want when the M&A cycle favors targets, not acquirers.

Over the past 12 months, XBI has posted a total return of roughly 74%. Its 52-week range runs from about $78 to $139. It's currently trading around $133.

When Big Pharma is writing checks to fill pipeline gaps, the companies they're buying tend to live inside XBI — not inside the S&P 500.

Bottom line: When the FDA is moving, M&A follows — and the best money is made by owning the right optionality before bankers start hyping it.

Before You Go

If you want biotech alpha, stop asking "is the science good?"

Start asking: "Is the FDA clearing the runway?"

That one question will keep you out of 80% of the traps.